Healthcare
Live Price
Offline$7.33
+5.09% today
1Y Change
+23.23%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ramsay Health Care Limited (RMYHY) is a Healthcare stock with a market cap of $8.80B and listed on OTC. The stock last traded around $7.33 and up 23.2% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +6.1%, EPS growth of -97.4%, a dividend yield of 2.2%. What stands out right now is revenue +6.1%, EPS -97.4%, free cash flow +30.6% with operating margin 8.5% and ROIC 5.7%. The dividend is present but secondary, with a yield around 2.2%. Valuation already assumes a fairly strong business story at P/E 30.4 and price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RMYHY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMYHY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RMYHY Max Drawdown
-30.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RMYHY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.9B
-2.4% YoY
FY Net Income
$449.0M
+63.9% YoY
Free Cash Flow
$887.2M
+7682.5% YoY
Revenue Growth
+6.1%
EPS Growth
-97.4%
Gross Margin
10.6%
Net Margin
1.6%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17.7B | 16.7B | 15.0B | 13.2B | 12.9B |
| Gross Profit | 13.7B | 2.0B | 1.3B | 901M | 833M |
| Operating Income | 871M | 833M | 1.6B | 231M | 1.6B |
| EBITDA | 1.6B | 1.8B | 1.8B | 1.6B | 1.8B |
| Net Income | 24M | 889M | 298M | 274M | 449M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 784M | 662M | 656M | 314M | 3.0B |
| Total Assets | 22.5B | 20.9B | 21.1B | 19.6B | 19.4B |
| Total Liabilities | 16.8B | 15.4B | 16.3B | 15.1B | 14.8B |
| Shareholder Equity | 5.0B | 4.9B | 4.2B | 3.9B | 4.0B |
| Total Debt | 12.1B | 10.9B | 11.9B | 10.7B | 10.6B |
| Net Debt | 11.3B | 10.3B | 11.2B | 10.4B | 7.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.5B
+110.6% YoY
Capital Expenditures
629M
+11.2% YoY
Free Cash Flow
887M
+7682.5% YoY
Key ratios
Gross Margin
10.6%
Operating Margin
8.5%
Net Margin
1.6%
ROE
5.8%
Debt / Equity
3.48x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.